Human Papillomavirus. Cervical high risk human papillomavirus (HPV) DNA test positive
Conditions
Interventions
Intervention 1: Control group: Patients received daily supplements including 220 mg of Zinc (Dana Pharma), 500 mg of Vitamin C (Donya Darou Pharmaceutical Co.), and 1000 IU of Vitamin D3 (Dana Pharma)
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
21 Years to 55 Years
Inclusion criteria
Inclusion criteria: Women with a positive HPV DNA test (PCR) Pap smear cytology report showing ASCUS or LSIL findings Women with no pregnancy or lactation No history of immunodeficiency Absence of a history of cone biopsy Absence of cardiac, renal, and hepatic disease No evidence of hepatitis B infection Absence of psychiatric or neurological disease Consent to participate in the study
Exclusion criteria
Exclusion criteria: Lack of cooperation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cervical cytology status. Timepoint: Baseline and 6-month follow-up. Method of measurement: Pap smear.;HPV clearance. Timepoint: Baseline and 6-month follow-up. Method of measurement: Pap smear.;HPV genotype. Timepoint: Baseline and 6-month follow-up. Method of measurement: Pap smear. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Maryam Maktabi
Arak University of Medical Sciences
Outcome results
None listed